ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT03672773

Public ClinicalTrials.gov record NCT03672773. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (TRIO-US L-07)

Study identification

NCT ID
NCT03672773
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Enrollment
35 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 30, 2018
Primary completion
Sep 30, 2026
Completion
Sep 30, 2027
Last update posted
Nov 9, 2025

2018 – 2027

United States locations

U.S. sites
6
U.S. states
4
U.S. cities
6
Facility City State ZIP Site status
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center Bakersfield California 93309
St. Joseph Heritage Healthcare Fullerton California 92835
UCLA / Jonsson Comprehensive Cancer Center Los Angeles California 90095
Orlando Health, Inc. d/b/a Orlando Health UF Health Center Orlando Florida 32806
Ft. Wayne Medical Oncology and Hematology, Inc. Fort Wayne Indiana 46804
Cancer Center of Kansas Wichita Kansas 67214

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03672773, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 9, 2025 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03672773 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →